Abstract 305P
Background
There is no evidence of effective follow-up for the detection of recurrent head and neck cancer (HNC). There are few reports on the frequency of relapse of platinum-resistant HNC in clinical practice. Local recurrence is often seen during the first two years during which follow-up computed tomography (CT)/magnetic resonance imaging is recommended. The occurrence rate of second cancer (SC) has been reported to be 14.5%.
Methods
We conducted a retrospective analysis to evaluate the clinical course in 374 patients with head and neck squamous cell carcinoma who underwent definitive treatment at our institute between January 1998 and November 2018. The observation period was until January 2019.
Results
Recurrence and/or metastasis of HNC (R/M HNC) and SC were seen in 128 and 34 patients, respectively. The sites of R/M HNC were the hypopharynx, oral cavity, and larynx in 30.5%, 21.9%, and 19.5% of the patients, respectively. The sites of SC were the larynx, hypopharynx, and oropharynx in 38.2%, 26.5%, and 20.6% of the patients, respectively. At the diagnosis of relapse of new cancer, 50% of patients with R/M HNC and 44.1% of those with SC were symptomatic. The most common symptom was pain, while other symptoms were swelling, loss of appetite, hoarseness, dysphagia, dyspnea, cough, and bleeding. The modality of detection of recurrence was highest with CT (60.2%), followed by endoscopy (14.1%) and medical examination (14.1%). The median time to recurrence was 6.9 (range, 0 − 141.8) months, with 75% of recurrences occurring within one year. Furthermore, 4.8% of the recurrences occurred after five years. Platinum-resistant relapse accounted for 26.6% of all patients with R/M HNC and 58.6% of the relapses occurred within six months. The median time to recurrence was 35.5 (range, 1.5 − 240.9) months, with 35.3% of the recurrences occurring after five years.
Conclusions
In clinical practice, it is important to note the timing of rescue treatment during the follow-up period, focusing on imaging and medical examinations and confirming the symptoms within one year of treatment for HNC. During the long-term follow-up, observation for suspected development of SC is necessary.
Clinical trial identification
.
Editorial acknowledgement
.
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
133P - Prognostic and predictive factors from the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in previously treated advanced hepatocellular carcinoma (aHCC)
Presenter: Thomas Yau
Session: Poster display session
Resources:
Abstract
134P - Identification, development and validation of a circulating miRNA-based diagnostic signature for early detection of gastric cancer
Presenter: Daisuke Izumi
Session: Poster display session
Resources:
Abstract
135P - The promising key genes associated with tumour microenvironment and prognosis of hepatocellular carcinoma
Presenter: Jing Fang
Session: Poster display session
Resources:
Abstract
136P - Helicobacter pylori-positive gastric diffuse large B-cell lymphoma: A subset with distinct prognostic features
Presenter: Yuan Cheng
Session: Poster display session
Resources:
Abstract
137P - Significant benefit of pyrotinib combined with SHR6390 in patients with multiline-resistant HER2-positive advanced gastric cancer
Presenter: Zuhua Chen
Session: Poster display session
Resources:
Abstract
138P - Incidence of supracarinal lymph node positivity in operated cases of total esophagectomy: Short term results from a tertiary cancer centre
Presenter: Akhil Palod
Session: Poster display session
Resources:
Abstract
139P - Prognostic usefulness of advanced lung cancer inflammation index in locally-advanced pancreatic carcinoma patients treated with radical chemoradiotherapy
Presenter: Ayberk Besen
Session: Poster display session
Resources:
Abstract
140P - Pancreaticoduodenectomy versus combined neoadjuvant chemotherapy and pancreaticoduodenectomy: Survival patterns among patients with stage II & III periampullary carcinoma
Presenter: Mai Abdelkader
Session: Poster display session
Resources:
Abstract
141P - A 13-gene signature of DNA repair predicts prognosis in gastric cancer patients
Presenter: Jinjia Chang
Session: Poster display session
Resources:
Abstract
142P - Relation between Interleukin -4 (590C/T) gene polymorphism and hepatocellular carcinoma risk in HBV and HCV patients
Presenter: Suzy Gohar
Session: Poster display session
Resources:
Abstract